<p>Three different doses of amantadine were acutely injected together with L-DOPA and a significant antidyskinetic effect was observed at the 10 mg/kg dose (A). Ethovision analysis of the total distance travelled (TDT) shows there is no effect on locomotor activity of either dose of amantadine tested (B). Sub-chronic 5-day treatment with 10 mg/kg amantadine further confirms the antidyskinetic efficacy of the compound (C) and the lack of significant effect on locomotor activity compared to vehicle treatment (D). Data are presented as mean ± s.e.m. Unpaired Student <i>t</i> test (*, p<0.05).</p
A double-blind crossover trial of amantadine vs. placebo was carried out involving 42 patients with ...
Parkinson's disease is traditionally viewed as a disease which affects the human motor sphere. Besid...
ADS-5102 is a long-acting, extended-release capsule formulation of amantadine HCl administered once ...
Dyskinesias are some of the major motor complications that impair quality of life for patients with ...
Background: Recent short-term studies suggested that aman-tadine (Ama) might ameliorate dyskinesia i...
l-DOPA induced dyskinesias (LIDs) may affect up to 40% of Parkinson’s disease (PD) and impact negati...
BACKGROUND: Dyskinesias are some of the major motor complications that impair quality of life for pa...
Background: Dyskinesias are some of the major motor complications that impair quality of life for pa...
Sixty-nine patients with Parkinson's disease were randomly allocated in a trial to compare the ...
The long-term therapy of Parkinson’s disease (PD) with dopaminergic drugs is naturally accompanied b...
This report covers a review of the literature and a description of a double-blind placebo-controlled...
Treatment of Parkinson’s disease (PD) includes the administration of dopaminergic and occasionally n...
Six patients with idiopathic Parkinsonism were treated with a combination of amantadine and L-dopa a...
It has been reported that non-Caucasian populations often suffer from an atypical type of Parkinson'...
Objective We examined whether amantadine can prevent the development of dyskinesia. Methods Patients...
A double-blind crossover trial of amantadine vs. placebo was carried out involving 42 patients with ...
Parkinson's disease is traditionally viewed as a disease which affects the human motor sphere. Besid...
ADS-5102 is a long-acting, extended-release capsule formulation of amantadine HCl administered once ...
Dyskinesias are some of the major motor complications that impair quality of life for patients with ...
Background: Recent short-term studies suggested that aman-tadine (Ama) might ameliorate dyskinesia i...
l-DOPA induced dyskinesias (LIDs) may affect up to 40% of Parkinson’s disease (PD) and impact negati...
BACKGROUND: Dyskinesias are some of the major motor complications that impair quality of life for pa...
Background: Dyskinesias are some of the major motor complications that impair quality of life for pa...
Sixty-nine patients with Parkinson's disease were randomly allocated in a trial to compare the ...
The long-term therapy of Parkinson’s disease (PD) with dopaminergic drugs is naturally accompanied b...
This report covers a review of the literature and a description of a double-blind placebo-controlled...
Treatment of Parkinson’s disease (PD) includes the administration of dopaminergic and occasionally n...
Six patients with idiopathic Parkinsonism were treated with a combination of amantadine and L-dopa a...
It has been reported that non-Caucasian populations often suffer from an atypical type of Parkinson'...
Objective We examined whether amantadine can prevent the development of dyskinesia. Methods Patients...
A double-blind crossover trial of amantadine vs. placebo was carried out involving 42 patients with ...
Parkinson's disease is traditionally viewed as a disease which affects the human motor sphere. Besid...
ADS-5102 is a long-acting, extended-release capsule formulation of amantadine HCl administered once ...